Form 4: Aura Biosciences Director Granted Significant Equity Awards

Sapna Srivastava, a Director at Aura Biosciences, Inc., was granted 13,000 restricted stock units and 17,000 stock options on June 17, 2025, as part of the company's incentive plan.

Summary

• Sapna Srivastava, a Director of Aura Biosciences, Inc. (AURA), reported the acquisition of equity securities on June 17, 2025.
• Ms. Srivastava was granted 13,000 shares of Common Stock through a Restricted Stock Unit (RSU) award under the Issuer's 2021 Stock Option and Incentive Plan, with an acquisition price of $0.
• These RSUs are set to vest in full upon the earlier of June 17, 2026, or the next annual meeting of stockholders, contingent on her continued service.
• Following this RSU acquisition, Ms. Srivastava beneficially owns 23,500 shares of Common Stock.
• Additionally, on June 17, 2025, Ms. Srivastava was granted 17,000 stock options with an exercise price of $6.18 per share, also with an acquisition price of $0 for the grant itself.
• These stock options will vest and become exercisable in full upon the earlier of June 17, 2026, or the next annual meeting of stockholders, subject to her continued service, and are set to expire on June 17, 2035.
• A Power of Attorney, dated March 28, 2025, was filed, appointing Conor Kilroy and Amy Elazzouzi to execute and file SEC reports on behalf of Ms. Srivastava.

Sentiment

Score: 7

Explanation: The document reports routine equity grants to a director, which is generally positive as it aligns insider interests with shareholders. It's not a major news event but indicates ongoing compensation practices and director commitment.

Positives

• The grant of equity awards (RSUs and stock options) to a director aligns her interests with those of shareholders, incentivizing long-term commitment and performance.
• The awards are part of the company's established 2021 Stock Option and Incentive Plan, indicating a structured and routine approach to executive and director compensation.

Risks

• The vesting of both the RSUs and stock options is contingent upon the reporting person's continued service as a director, meaning the awards could be forfeited if service ceases before the vesting date.
• The financial benefit from the stock options is dependent on the future market price of Aura Biosciences' common stock exceeding the exercise price of $6.18 per share.

Future Outlook

The vesting of the granted restricted stock units and stock options is contingent upon the director's continued service until at least June 17, 2026, or the next annual meeting of stockholders, whichever occurs earlier, indicating a future commitment period for the director and a potential increase in her beneficial ownership of vested shares and exercisable options.

Industry Context

This Form 4 filing reflects a standard practice in the biotechnology or pharmaceutical industry, where equity compensation, including restricted stock units and stock options, is commonly used to attract, retain, and incentivize directors and key personnel. Such awards align the interests of insiders with long-term shareholder value creation, a common strategy in growth-oriented sectors like biotech where long development cycles and significant capital investment are typical.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and stock options for director compensation is a widely accepted and standard practice across various industries, particularly in high-growth and research-intensive sectors like biotechnology.
• The vesting schedule, tied to continued service and specific dates or corporate events (like annual meetings), is consistent with corporate governance best practices aimed at retaining talent and aligning incentives over a multi-year horizon.
• While the specific size of the awards (13,000 RSUs and 17,000 options) can vary significantly based on the company's market capitalization, stage of development, and the individual's role and contribution, the structure of the compensation package itself aligns with typical industry benchmarks for director equity grants.

Corporate Governance

Stakeholder Impact

• **Shareholders:** The equity grants align the director's financial interests with long-term shareholder value, potentially fostering more strategic decision-making aimed at stock appreciation. The awards are part of a pre-approved incentive plan, and any potential dilution is expected and typically factored into compensation strategies.
• **Employees:** While not directly impacting employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel and maintaining a competitive compensation framework.

Next Steps

• Continued service of Sapna Srivastava as a director of Aura Biosciences, Inc. for the RSUs and stock options to vest.
• The occurrence of the next annual meeting of the Issuer's stockholders, which serves as an alternative vesting trigger for the awards.
• Potential exercise of stock options by Sapna Srivastava on or after June 17, 2026, or the next annual meeting, and before June 17, 2035, assuming the stock price is favorable.

Key Dates

Keywords

Aura Biosciences, AURA, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Stock Options, Equity Compensation, Director Compensation, Beneficial Ownership, SEC Filing